These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 34170505)
1. Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database. Weil-Olivier C; Taha MK; Emery C; Bouée S; Beck E; Aris E; Loncle-Provot V; Nachbaur G; Pribil C Infect Dis Ther; 2021 Sep; 10(3):1607-1623. PubMed ID: 34170505 [TBL] [Abstract][Full Text] [Related]
2. Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease-Real-World Data Analysis Using the French National Claims Database (SNIIRAM). Shen J; Bouée S; Aris E; Emery C; Beck EC Infect Dis Ther; 2022 Feb; 11(1):249-262. PubMed ID: 34791633 [TBL] [Abstract][Full Text] [Related]
3. Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database. Huang L; Heuer OD; Janßen S; Häckl D; Schmedt N PLoS One; 2020; 15(1):e0228020. PubMed ID: 31990941 [TBL] [Abstract][Full Text] [Related]
4. Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Weil-Olivier C; Taha MK; Bouée S; Emery C; Loncle-Provot V; Nachbaur G; Beck E; Pribil C Hum Vaccin Immunother; 2022 Dec; 18(1):2021764. PubMed ID: 35192785 [TBL] [Abstract][Full Text] [Related]
5. Lifetime cost of meningococcal disease in France: Scenarios of severe meningitis and septicemia with purpura fulminans. Bénard S; Wright C; Voisine J; Olivier CW; Gaudelus J J Infect Public Health; 2016; 9(3):339-47. PubMed ID: 26688376 [TBL] [Abstract][Full Text] [Related]
6. A database study of clinical and economic burden of invasive meningococcal disease in France. Huang L; Fievez S; Goguillot M; Marié L; Bénard S; Elkaïm A; Tin Tin Htar M PLoS One; 2022; 17(4):e0267786. PubMed ID: 35486581 [TBL] [Abstract][Full Text] [Related]
7. Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands-a Holistic Approach. Zeevat F; Simons JJM; Westra TA; Wilschut JC; van Sorge NM; Boersma C; Postma MJ Infect Dis Ther; 2024 Mar; 13(3):481-499. PubMed ID: 38366286 [TBL] [Abstract][Full Text] [Related]
8. Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment). Fernandes J; Bregman B; Combemale P; Amaz C; de Léotoing L; Vainchtock A; Gaudin AF BMC Health Serv Res; 2017 Aug; 17(1):542. PubMed ID: 28789648 [TBL] [Abstract][Full Text] [Related]
9. Health economic impact of patients with phenylketonuria (PKU) in France - A nationwide study of health insurance claims data. Arnoux JB; Douillard C; Maillot F; Bouée S; Jacob C; Schneider KM; Theil J; Charrière S Mol Genet Metab Rep; 2024 Dec; 41():101134. PubMed ID: 39253300 [TBL] [Abstract][Full Text] [Related]
10. Economic burden of meningococcal disease in children and adolescents in Tijuana, Mexico. Chacon-Cruz E; Lopatynsky-Reyes EZ; Huerta-Garcia G; Cervantes-Apolinar MY; Guzman-Holst A; Van Oorschot D Hum Vaccin Immunother; 2022 Nov; 18(6):2103319. PubMed ID: 35921223 [TBL] [Abstract][Full Text] [Related]
11. Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Taha MK; Weil-Olivier C; Bouée S; Emery C; Nachbaur G; Pribil C; Loncle-Provot V Hum Vaccin Immunother; 2021 Jun; 17(6):1858-1866. PubMed ID: 33449835 [TBL] [Abstract][Full Text] [Related]
12. Costs and mortality associated with HIV: a machine learning analysis of the French national health insurance database. Prodel M; Finkielsztejn L; Roustand L; Nachbaur G; De Leotoing L; Genreau M; Bonnet F; Ghosn J J Public Health Res; 2021 Nov; 11(2):. PubMed ID: 34850620 [TBL] [Abstract][Full Text] [Related]
13. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Wang B; Haji Ali Afzali H; Marshall H Vaccine; 2014 Aug; 32(37):4791-8. PubMed ID: 24998605 [TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I Encephale; 2005; 31(2):235-46. PubMed ID: 15959450 [TBL] [Abstract][Full Text] [Related]
16. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Scholz S; Koerber F; Meszaros K; Fassbender RM; Ultsch B; Welte RR; Greiner W Vaccine; 2019 Mar; 37(12):1692-1701. PubMed ID: 30661834 [TBL] [Abstract][Full Text] [Related]
17. Migraine burden and costs in France: a nationwide claims database analysis of triptan users. Donnet A; Emery C; Aly S; Allaf B; Cayre F; Mahieu N; Gourmelen J; Levy P; Fagnani F J Med Econ; 2019 Jul; 22(7):616-624. PubMed ID: 30836035 [No Abstract] [Full Text] [Related]
18. Understanding the Sequelae of Invasive Meningococcal Disease in the United States. Marshall GS; McCormick ZL; Johns JS; Verduzco-Gutierrez M; Herrera-Restrepo O; Harrison LH Infect Dis Ther; 2024 Nov; 13(11):2213-2220. PubMed ID: 39269567 [TBL] [Abstract][Full Text] [Related]
19. Epidemiology and disease burden of tuberous sclerosis complex in France: A population-based study based on national health insurance data. Fagnani F; Laurendeau C; de Zelicourt M; Marshall J Epilepsia Open; 2022 Dec; 7(4):633-644. PubMed ID: 36029029 [TBL] [Abstract][Full Text] [Related]
20. Lifetime costs of invasive meningococcal disease: A Markov model approach. Wang B; Haji Ali Afzali H; Giles L; Marshall H Vaccine; 2019 Oct; 37(46):6885-6893. PubMed ID: 31594708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]